Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Camp Hill, PA
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Camp Hill, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Rapid City, SD
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Oak Ridge, TN
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Oak Ridge, TN
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Amarillo, TX
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Dallas, TX
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Fort Worth, TX
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Round Rock, TX
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Victoria, TX
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Victoria, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Kogarah,
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Kogarah,
Click here to add this to my saved trials
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
mi
from
Saint Petersburg, FL
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Birmingham, AL
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Aurora, CO
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Atlanta, GA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Rochester, MN
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Durham, NC
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Cleveland, OH
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Houston, TX
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Richmond, VA
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Calgary,
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery
The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography
Status: Enrolling
Updated:  11/6/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery
The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography
Status: Enrolling
Updated: 11/6/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension
Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery
Status: Enrolling
Updated:  11/6/2017
Novant Health Forsyth Medical Center
mi
from
Winston-Salem, NC
Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension
Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery
Status: Enrolling
Updated: 11/6/2017
Novant Health Forsyth Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated:  11/6/2017
Cedars-Sinai Health System
mi
from
Los Angeles, CA
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated: 11/6/2017
Cedars-Sinai Health System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated:  11/6/2017
Louisiana State University
mi
from
New Orleans, LA
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated: 11/6/2017
Louisiana State University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated:  11/6/2017
The University Of Texas
mi
from
Houston, TX
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated: 11/6/2017
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated:  11/6/2017
Univ of Washington
mi
from
Seattle, WA
Understanding the Genetic and Hereditary Basis of Atherosclerosis
SNPs and Extent of Atherosclerosis (SEA) Study
Status: Enrolling
Updated: 11/6/2017
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
Status: Enrolling
Updated:  11/6/2017
Wake Forest University Baptist Medical Center - Emergency Department
mi
from
Winston-Salem, NC
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
Status: Enrolling
Updated: 11/6/2017
Wake Forest University Baptist Medical Center - Emergency Department
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Status: Enrolling
Updated:  11/7/2017
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Status: Enrolling
Updated: 11/7/2017
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function
A Randomized, Single Blind, Comparative Trial of Standardized 12 Lead ECG to the 12 Lead ECG Glove for the Assessmant of Cardiac Electrical Function
Status: Enrolling
Updated:  11/7/2017
New York Univ. Medical Center
mi
from
New York, NY
A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function
A Randomized, Single Blind, Comparative Trial of Standardized 12 Lead ECG to the 12 Lead ECG Glove for the Assessmant of Cardiac Electrical Function
Status: Enrolling
Updated: 11/7/2017
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study
Status: Enrolling
Updated:  11/8/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study
Status: Enrolling
Updated: 11/8/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Statin Therapy to Improve Atherosclerosis in HIV Patients
Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients
Status: Enrolling
Updated:  11/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Statin Therapy to Improve Atherosclerosis in HIV Patients
Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients
Status: Enrolling
Updated: 11/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation
A Randomized Controlled Trial of Computer-Driven Weaning Compared With Standard of Care Weaning in Medical Patients Requiring Mechanical Ventilation
Status: Enrolling
Updated:  11/9/2017
Boston Med Ctr
mi
from
Boston, MA
Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation
A Randomized Controlled Trial of Computer-Driven Weaning Compared With Standard of Care Weaning in Medical Patients Requiring Mechanical Ventilation
Status: Enrolling
Updated: 11/9/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients
Status: Enrolling
Updated:  11/10/2017
Lehigh Valley Hospital - Muhlenberg
mi
from
Bethlehem, PA
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients
Status: Enrolling
Updated: 11/10/2017
Lehigh Valley Hospital - Muhlenberg
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
The Heart Center, PC
mi
from
Huntsville, AL
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
The Heart Center, PC
mi
from
Huntsville, AL
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Sutter Memorial Hospital
mi
from
Sacramento, CA
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Sutter Memorial Hospital
mi
from
Sacramento, CA
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Yale University School of Medicine
mi
from
New Haven, CT
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Holy Cross Medical Group
mi
from
Coral Springs, FL
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Holy Cross Medical Group
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Emory University
mi
from
Atlanta, GA
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
University Cardiology Associates, LLC
mi
from
Augusta, GA
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
University Cardiology Associates, LLC
mi
from
Augusta, GA
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Fox Valley Clinical Research Center, LLC
mi
from
Aurora, IL
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Fox Valley Clinical Research Center, LLC
mi
from
Aurora, IL
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Krannert Institute of Cardiology
mi
from
Indianapolis, IN
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Krannert Institute of Cardiology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
University of Maryland
mi
from
Baltimore, MD
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Metropolitan Cardiovascular Consultants
mi
from
Beltsville, MD
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Metropolitan Cardiovascular Consultants
mi
from
Beltsville, MD
Click here to add this to my saved trials
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated:  11/10/2017
Massachusetts General Hospital
mi
from
Boston, MA
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Status: Enrolling
Updated: 11/10/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials